FINWIRES · TerminalLIVE
FINWIRES

ADP表示,4月份私营部门招聘增速创下自2025年1月以来的最快水平。

By

-- 美国就业数据公司ADP周三公布的数据显示,4月份美国私营部门就业增速创一年多来新高,官方就业报告将于本周晚些时候发布。 薪资处理公司ADP表示,上月私营部门新增就业岗位10.9万个,创下自2025年1月以来的最快增速。彭博社汇总的一项调查显示,市场普遍预期新增就业岗位12万个。 ADP数据显示,3月份新增就业岗位数量从6.2万个下调至6.1万个。 牛津经济研究院高级美国经济学家马修·马丁在一份发给的报告中表示:“ADP就业报告显示私营部门就业人数增长,这不仅表明劳动力市场稳定,而且表明尽管伊朗战争爆发,劳动力市场仍有可能回暖。” “如果周五公布的官方数据也反映出这一信号,鉴于盈亏平衡点很低(我们估计接近于零),失业率可能会下降。” 据彭博社汇总的一项调查显示,美国劳工统计局预计将于周五公布的数据显示,4月份美国非农就业人数增加了6.5万人,低于3月份的17.8万人。失业率预计将维持在4.3%不变。 ADP表示,上个月服务业新增就业岗位9.4万个,其中教育和医疗服务业增幅最大,达到6.1万人。贸易、运输和公用事业就业人数反弹,增加了2.5万人,而专业和商业服务业则减少了8000人。商品生产行业的就业人数增加了1.5万人。 ADP首席经济学家内拉·理查森表示:“小型和大型雇主都在招聘,但我们看到中型企业的招聘活动有所疲软。” “大型企业拥有可部署的资源,而小型企业则最为灵活,这在复杂的劳动力市场环境中都是重要的优势。” 据ADP数据显示,4月份大中小型企业共新增就业岗位超过10万个,其中中型企业新增就业岗位2000个。 报告显示,4月份留任者的年工资环比增长略微放缓至4.4%,而跳槽者的薪酬增长则保持稳定,为6.6%。 周二,美国劳工统计局(BLS)报告称,3月份职位空缺数量有所下降,但招聘人数有所上升。

Price: $207.19, Change: $-3.41, Percent Change: -1.62%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL